sorafenib has been researched along with Peritoneal Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inayat, F; Lodhi, HT; Ullah, W; Zafar, F | 1 |
| Kim, DY; Kim, YJ; Lee, SJ; Lim, HY; Lim, TS; Park, JW; Ryoo, BY; Yoo, C; Yu, SJ | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T | 1 |
| Baumbusch, T; Hastka, J; Metzgeroth, G; Reiter, A; Ströbel, P | 1 |
| Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C | 1 |
| Birrer, MJ; Bristow, RE; Calvert, V; Cohn, D; DeGeest, K; Farley, J; Lankes, HA; Matei, D; Mutch, D; Petricoin, EF; Sill, MW; Yamada, SD | 1 |
| Bodnar, L; Górnas, M; Szczylik, C | 1 |
| Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C | 1 |
1 review(s) available for sorafenib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Peritoneal Neoplasms; Peritoneum; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Young Adult | 2010 |
5 trial(s) available for sorafenib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan | 2011 |
4 other study(ies) available for sorafenib and Peritoneal Neoplasms
| Article | Year |
|---|---|
Primary peritoneal hepatoid adenocarcinoma: a diagnostic and therapeutic conundrum in patients with gastrointestinal bleeding.
Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Antineoplastic Agents; Carcinoma, Hepatocellular; Docetaxel; Fatty Liver; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Peritoneal Neoplasms; Sorafenib | 2018 |
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2010 |